Jump to ContentJump to Main Navigation
The Cuban CureReason and Resistance in Global Science$
Users without a subscription are not able to see the full content.

S. M. Reid-Henry

Print publication date: 2010

Print ISBN-13: 9780226709178

Published to Chicago Scholarship Online: March 2013

DOI: 10.7208/chicago/9780226709192.001.0001

Show Summary Details
Page of

PRINTED FROM CHICAGO SCHOLARSHIP ONLINE (www.chicago.universitypressscholarship.com). (c) Copyright University of Chicago Press, 2022. All Rights Reserved. An individual user may print out a PDF of a single chapter of a monograph in CHSO for personal use.date: 28 May 2022

Peripheral Assent

Peripheral Assent

(p.139) Seven Peripheral Assent
The Cuban Cure
University of Chicago Press

This chapter examines the growth of the biotechnology sector in Cuba. It explores Cuba's various attempts to define its biotechnology and its efforts to maintain a space for that science amid a rather differently couched global pharmaceutical norm. It mentions that the Center for Molecular Immunology's (CIM) TheraCIM drug was granted a U.S. patent in 1999 and an in-depth article on the CIM–York Medical partnership was featured in the July 2000 issue of Journal of the National Cancer Institute.

Keywords:   biotechnology, Cuba, global pharmaceutical norm, CIM, TheraCIM, drug patent, York Medical, Jounral of the National Cancer Institute

Chicago Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs, and if you can't find the answer there, please contact us.